Biogen CEO George Scangos said in a conference call accompanying the announcement that the time was right to spin off the hemophilia franchise, insisting the move will make both companies stronger. "The business has matured, it's profitable, it's growing, it can stand on its own, it has a pipeline," he claimed. It would have been "premature," he added, to make the move six or 12 months ago, which is why this outcome had not been considered any earlier.
Premature is likely an accurate description of the hemophilia business, even now. Eloctate and Alprolix, the hemophilia A and hemophilia...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
